- Home
- MSB vs CERS Comparison
MSB vs CERS Comparison
Compare MSB & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MSB
- CERS
- Stock Information
- Founded
- MSB 1961
- CERS 1991
- Country
- MSB United States
- CERS United States
- Employees
- MSB N/A
- CERS N/A
- Industry
- MSB Metal Mining
- CERS EDP Services
- Sector
- MSB Basic Materials
- CERS Technology
- Exchange
- MSB Nasdaq
- CERS Nasdaq
- Market Cap
- MSB 323.0M
- CERS 324.3M
- IPO Year
- MSB N/A
- CERS 1997
- Fundamental
- Price
- MSB $26.20
- CERS $1.79
- Analyst Decision
- MSB
- CERS Buy
- Analyst Count
- MSB 0
- CERS 3
- Target Price
- MSB N/A
- CERS $3.17
- AVG Volume (30 Days)
- MSB 23.1K
- CERS 1.8M
- Earning Date
- MSB 01-01-0001
- CERS 10-30-2024
- Dividend Yield
- MSB 5.99%
- CERS N/A
- EPS Growth
- MSB 160.54
- CERS N/A
- EPS
- MSB 1.35
- CERS N/A
- Revenue
- MSB $23,864,419.00
- CERS $176,229,000.00
- Revenue This Year
- MSB N/A
- CERS $26.47
- Revenue Next Year
- MSB N/A
- CERS $11.48
- P/E Ratio
- MSB $19.34
- CERS N/A
- Revenue Growth
- MSB 147.28
- CERS 14.71
- 52 Week Low
- MSB $15.93
- CERS $1.38
- 52 Week High
- MSB $26.99
- CERS $2.59
- Technical
- Relative Strength Index (RSI)
- MSB 59.75
- CERS 52.76
- Support Level
- MSB $25.26
- CERS $1.63
- Resistance Level
- MSB $26.80
- CERS $2.03
- Average True Range (ATR)
- MSB 0.92
- CERS 0.12
- MACD
- MSB -0.06
- CERS -0.00
- Stochastic Oscillator
- MSB 59.69
- CERS 52.94
About MSB Mesabi Trust
Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of the assets held. The company's principally wholly-owned segment is the iron ore mining segment and it generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the eastern end of the Mesabi Iron Range.
About CERS Cerus Corporation
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.